Zacytuj

Lethal dose (LD50), minimum inhibitory concentration (MIC) and mean larval development ±SD at MIC thresholds for the three classes of anthelmintics obtained from the in vitro larval development tests

Drug Larval development test
LD50 MIC L3 larvae (%) ± SD at MIC
Thiabendazole 0.37 n.a. 56.31 ± 5.19
Ivermectin 28.87 173.6 45.73 ± 6.32
Levamisole 0.10 1.0 0 ± 0

Results of the morphological identification of third-stage larvae before and after treatment with albendazole (ALB), ivermectin (IVM) and levamisole (LEV)

Species Before treatment (%) After treatment (%)
ALB IVM LEV
Haemonchus contortus 77 100 100
Trichostrongylus spp. 13
Teladorsagia spp. 7
Oesophagostomum/Chabertia spp. 3

Mean hatching (in %) with standard deviation (SD) and mean of ED50 from the in vitro egg hatch test

TBZ concentration (μg/mL) Mean hatching (%) ±SD
Control 96.25 0.43
0.05 96.00 1.22
0.1 91.25 4.22
0.3 84.00 1.73
0.5 71.50 4.55
1 54.50 3.22
Mean ED50 ± SD 1.22 0.08

Results of the in vivo faecal egg count reduction test (FECRT): percent reduction 10 days after treatment in both phases of the trial

  Group (n = 10)/Treatment Mean EPG ± SD FECR(%)
Cabaret and Berrag formula (2004) (5) Kochapakdee formula (1995)(16)
Phase 1 G1 Albendazole single dose
     D0 370 ± 205 0 0
     D10 1,465 ± 1,482
G2 Albendazole fasting dose
     D0 1,525 ± 1,212 16.90 13.70
     D10 1,317 ± 986
G3 Albendazole divided dose
     D0 710 ± 326 0 0
     D10 1,400 ± 794
G4 Albendazole double dose
     D0 605 ± 321 0 0
     D10 1,680 ± 1,803
G5 Ivermectin
     D0 350 ± 345 39.97 31.50
     D10 240 ± 232
Phase 2 Levasmisole
     D0 2,233 ± 2,045 100 100
     D10 0
Control
     D0 2,436 ± 1,239    
     D10 2,297 ± 968
eISSN:
2450-8608
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Life Sciences, Molecular Biology, Microbiology and Virology, other, Medicine, Veterinary Medicine